FDA 2024: Watch For Trial-Diversity Guidance, Final Quality Systems Rewrite
Executive Summary
Industry observers at RAPS Convergence in Montreal last week said the FDA’s agenda for 2024 is likely to include increased emphasis on MDUFA goals, enhanced cybersecurity requirements, the new QMSR, and more.